Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, fondata nel 1982. In collaborazione con l'Associazione Culturale Pediatri.
Login Abbonamenti Pubblicazioni Carrello Registrazione Perché registrarsi? Contatti

Caso contributivo

PDF

Diagnosi di malattia di Pompe nel neonato

Diagnosis of Pompe disease in a newborn

Carolina Amador1, Michele Sacchini2, Elisabetta Agostini3, Elena Procopio2, Emanuela Laudani3, Patrizio Fiorini3
1Scienze Biomediche dell’Età Evolutiva; 2UO di Malattie Metaboliche e Muscolari Ereditarie, 3UO di Terapia Intensiva Neonatale, Azienda Ospedaliero Universitaria Meyer, Firenze

Giugno 2014

Abstract
Pompe disease is an autosomal recessive storage disorder caused by a deficiency in the enzyme α-glucosidase, resulting in intralysosomal glycogen accumulation in skeletal and cardiac muscle. The classic infantile form is characterized by progressive hypertrophic cardiomyopathy, hypotonia and macroglossia with onset during the first months of life. The article reports on the case of Y., a newborn who presented with hypertrophic cardiomyopathy and who was diagnosed with Pompe disease within the first 14 days of life. The case emphasizes that a cardiomyopathy present in the first days of life, even in the absence of hypotonia, can be a signal for Pompe disease. An early diagnosis is crucial because it allows the introduction of enzyme replacement therapy and leads to a better outcome. The enzymatic analysis on drop blood sample is a quick, minimally invasive and easy method applicable to a newborn with cardiomyopathy of unknown origin.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Bibliografia
  • Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004;144:S35-43.
  • Pascual SI. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme. Adv Exp Med Biol 2009;652:39-46.
  • Pellegrini N, Laforet P, Orlikowski D, et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 2005;26:1024-31.
  • Bembi B, Cerini E, Danesino C, et al. Management and treatment of glycogenosis type II. Neurology 2008;71:12-36.
  • Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D; Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-6.
  • Wang RY, Bodamer OA, Watson MS, Wilcox WR; ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 2011;13:457-84.
  • Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenosis type II. Neurology 2008;71:S4-11.
  • Rajan DS, Abdel-Hamid H. Child neurology: Pompe disease: new horizons. Neurology 2012;79:e197-200.
  • Bodamer OA, Dajnoki A. Diagnosing lysosomal storage disorders: Pompe disease. Curr Protoc Hum Genet 2012;17:17.11.
  • Dubrovsky A, Corderi J, Karasarides T, Taratuto AL. Pompe disease, the must-not-miss diagnosis: A report of 3 patients. Muscle Nerve 2012;47:594-600.
  • Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66:329-35.
  • Ansong AK, Li JS, Nozik-Grayck E, et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 2006;8:297-301.
  • Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet 2012;160:69-79.
  • Koeberl DD, Luo X, Sun B, et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab 2011;103:107-12.
  • Richard E, Douillard-Guilloux G, Caillaud C. New insights into therapeutic options for Pompe disease. IUBMB Life 2011;63:979-86.
  • Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012;14:135-42.
  • Cousens LP, Mingozzi F, van der Marel S, et al. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother 2012;8:1459-64.
  • Abbott MA, Prater SN, Banugaria SG, et al. Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab 2011;104:583-6.
  • Bali DS, Goldstein JL, Banugaria S, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 2012;160:40-9.
  • Khallaf HH, Propst J, Geffrard S, Botha E, Pervaiz MA. CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy. JIMD Rep 2013;9:133-7.
  • Banugaria SG, Prater SN, Patel TT, et al. Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT. PLoS One 2013;8:e67052.
  • Rohrbach M, Klein A, Köhli-Wiesner A, et al. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 2010;33:751-7.
  • Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008;122:39-45.
  • Dajnoki A, Mühl A, Fekete G, et al. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem 2008;54:1624-9.